XFIBRA, INC.
Biotech · Private
XFB19, an interference peptide therapeutic targeting C/EBPβ phosphorylation for pulmonary inflammation and fibrosis
- Grants
- $4.2M
- 6 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201420162018202020222024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Targeting C/EBP-beta Phosphorylation for the Treatment of Lung Fibrosis | $316,111 | |
| Federal grant | Department of Health and Human Services · Phase II · Treatment Of Lung Fibrosis : Ind Pharmacology And Toxicology | $224,967 | |
| Federal grant | Department of Health and Human Services · Phase II · Treatment Of Liver Injury And Fibrosis: Safety Pharmacology And Toxicology | $214,260 | |
| Federal grant | Department of Health and Human Services · Phase II · Treatment Of Liver Injury And Fibrosis: Safety Pharmacology And Toxicology | $1,136,111 | |
| Federal grant | Department of Health and Human Services · Phase II · Treatment Of Lung Fibrosis : Ind Pharmacology And Toxicology | $1,326,982 | |
| Federal grant | Department of Health and Human Services · Phase II · An Agnostic, Host-Direct Survival Cure MCM for Pulmonary Toxicants. | $999,601 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2375 | Indapta Therapeutic | — | — |
| 2376 | BIOINVENU CORPORATION | — | — |
| 2377 | DNP THERAPEUTICS INC | — | $470K |
| 2378 | XFIBRA, INC. | — | — |
| 2379 | ISIS PHARMACEUTICALS INC | — | $201M |
| 2380 | MANUS BIO INC | — | $109M |
| 2381 | Jaguar Health, Inc. | — | $146M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.